Working… Menu

A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration (ESCAPE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02194166
Recruitment Status : Completed
First Posted : July 18, 2014
Last Update Posted : June 10, 2019
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 12, 2018
Actual Study Completion Date : July 12, 2018